NASDAQ:PETX - Aratana Therapeutics Stock Price, News, & Analysis

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $7.36 million during the quarter, compared to the consensus estimate of $6.98 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. View Aratana Therapeutics' Earnings History.

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Aratana Therapeutics.

4 brokers have issued 12 month target prices for Aratana Therapeutics' stock. Their forecasts range from $4.14 to $5.00. On average, they expect Aratana Therapeutics' share price to reach $4.7250 in the next year. This suggests that the stock has a possible downside of 3.4%. View Analyst Price Targets for Aratana Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.

Headlines about PETX stock have trended positive on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Aratana Therapeutics.

Some companies that are related to Aratana Therapeutics include ZIOPHARM Oncology (ZIOP), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), ArQule (ARQL), Theravance Biopharma (TBPH), ANI Pharmaceuticals (ANIP), Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Omeros (OMER), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Axsome Therapeutics (AXSM) and Retrophin (RTRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Exelixis (EXEL), BioDelivery Sciences International (BDSI), Pieris Pharmaceuticals (PIRS), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and Micron Technology (MU).

Aratana Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include General American Investors Co. Inc. (2.89%), Acadian Asset Management LLC (0.90%), Assenagon Asset Management S.A. (0.40%), NJ State Employees Deferred Compensation Plan (0.14%), Bank of Montreal Can (0.09%) and State Board of Administration of Florida Retirement System (0.08%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

PETX stock was sold by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., State Board of Administration of Florida Retirement System, Assenagon Asset Management S.A., Menta Capital LLC and Bank of Montreal Can. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

PETX stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, NJ State Employees Deferred Compensation Plan, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Hunter Associates Investment Management LLC, Atlas Capital Advisors LLC, Adams Asset Advisors LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Aratana Therapeutics.

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PETX stock can currently be purchased for approximately $4.89.

Aratana Therapeutics has a market capitalization of $239.46 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.

The official website for Aratana Therapeutics is http://www.aratana.com/.

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]